Clinical Trials Logo
  1. Home
  2. Leukemia, Myeloid, Chronic
  3. NCT00732186

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Leukemia, Myeloid, Chronic Clinical Trial

Official title:
Phase Ib Study Evaluating the Safety and Exploring the Molecular and Cytogenetic Response of Combination Therapy With Dasatinib and Ipilimumab in Patients With Chronic or Accelerated Phase Chronic Myeloid Leukemia

Clinical Trial Summary

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00732186
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Withdrawn
Phase Phase 1
Start date August 2009
Completion date February 2011
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Completed NCT00759837 - Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects Phase 1
Completed NCT00538109 - An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase N/A
Completed NCT00040105 - Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia Phase 1
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Recruiting NCT01015742 - Unrelated Double Umbilical Cord Blood Units Transplantation Phase 2/Phase 3
Completed NCT00406393 - Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Phase 3
Completed NCT00246662 - Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies Phase 1
Completed NCT00264160 - Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy Phase 2/Phase 3
Terminated NCT00306332 - T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Phase 3
Terminated NCT00058747 - AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ Phase 2
Active, not recruiting NCT00538447 - Prospective Database for Chronic Myelogenous Leukemia N/A
Terminated NCT01050946 - Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit Phase 2
Completed NCT00034684 - Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) Phase 1/Phase 2
Recruiting NCT04260022 - Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Phase 1
Terminated NCT00167180 - Post Transplant Donor Lymphocyte Infusion Phase 2
Terminated NCT00449761 - Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase Phase 2
Completed NCT00455221 - Safety Assessment of a Multipeptide-gene Vaccine in CML Phase 1
Completed NCT00298987 - A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate Phase 2